Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies

被引：20

作者：

De Stefano, Nicola ^{[1
,2
]}

Sormani, Maria Pia ^{[3
,4
]}

Giovannoni, Gavin ^{[5
]}

Rammohan, Kottil ^{[6
]}

Leist, Thomas ^{[7
]}

Coyle, Patricia K. ^{[8
]}

Dangond, Fernando ^{[9
]}

Keller, Birgit ^{[10
]}

Alexandri, Nektaria ^{[10
]}

Galazka, Andrew ^{[10
]}

机构：

[1] Univ Siena, Dept Med Surg & Neurosci, Viale Bracci 2, I-53100 Siena, Italy

[2] Univ Siena, Dept Neurol & Behav Sci, Siena, Italy

[3] Univ Genoa, Dept Hlth Sci, Genoa, Italy

[4] Osped Policlin San Martino IRCCS, Genoa, Italy

[5] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England

[6] Univ Miami, Sch Med, Dept Neurol, MS Res Ctr, Miami, FL USA

[7] Jefferson Univ, Comprehens MS Ctr, Div Clin Neuroimmunol, Philadelphia, PA USA

[8] SUNY Stony Brook, Dept Neurol, Stony Brook, NY 11794 USA

[9] EMD Serono Res & Dev Inst Inc, Billerica, MA USA

[10] Merck KGaA, Darmstadt, Germany

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 01期

关键词：

Relapsing-remitting multiple sclerosis; relapses; hospitalisation; steroids; cladribine tablets; disease-modifying therapy; QUALITY-OF-LIFE; TRIAL;

D O I：

10.1177/13524585211010294

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: In the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study of patients with relapsing-remitting multiple sclerosis, treatment with cladribine tablets 3.5 mg/kg (CladT) significantly reduced the annualised relapse rate (ARR) versus placebo; this effect was sustained in CLARITY Extension, without further treatment. Objective: To assess the frequency and severity of relapses in patients treated with CladT versus placebo in CLARITY over 2 years and evaluate the durability of effect in patients who received no further treatment for 2 years in CLARITY Extension. Methods: In this post hoc analysis, ARRs were calculated for qualifying and all relapses, and qualifying and all severe relapses (i.e. requiring steroid treatment or leading to hospitalisation) in patients treated with CladT (n = 433) and placebo (n = 437) in CLARITY, and those from the CladT group who received placebo in CLARITY Extension (n = 98). Results: At Month 6, Year 1 and Year 2, patients receiving CladT had a significantly lower risk of qualifying or all relapses (all p < 0.0001), and qualifying or all severe relapses (all p < 0.005), compared with placebo. This effect was sustained in CLARITY Extension without further treatment. Conclusion: The results show durable efficacy of cladribine tablets 3.5 mg/kg for reducing frequency and severity of relapses in patients with relapsing-remitting multiple sclerosis. CLARITY: NCT00213135; CLARITY Extension: NCT00641537

引用

页码：111 / 120

页数：10

共 50 条

[41] Efficacy Outcomes In Cladribine Tablets-treated Patients In CLARITY Were Similar Between Patients Who Did Vs. Did Not Enter CLARITY Extension
Comi, G.
Soelberg-Sorensen, P.
Rammohan, K.
Giovannoni, G.
Damian, D.
Jack, D.
Dangond, F.
Galazka, A.
Jones, D. L.
Vermersch, P.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 43 - 43
[42] The CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY): design of a Phase III trial of oral cladribine in relapsing multiple sclerosis
Giovannoni, G.
Comi, G.
Cook, S.
Beelke, M.
Rieckmann, P.
Sorensen, P. S.
Vermersch, P.
MULTIPLE SCLEROSIS, 2007, 13 : S245 - S245
[43] Cladribine tablets produce selective and discontinuous reduction in B and T lymphocytes and natural killer cells in patients with early and relapsing multiple sclerosis (ORACLE-MS, CLARITY and CLARITY extension)
Stuve, Olaf
Soelberg-Sorensen, Per
Giovannoni, Gavin
Leist, Thomas
Hyvert, Yann
Damian, Doris
Boschert, Ursula
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP6 - NP6
[44] Cladribine tablets produce selective and discontinuous reduction of B and T lymphocytes and natural killer cells in patients with early and relapsing multiple sclerosis (ORACLE-MS, CLARITY and CLARITY Extension)
Stuve, O.
Soelberg-Sorensen, P.
Giovannoni, G.
Leist, T.
Hyvert, Y.
Damian, D.
Boschert, U.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 335 - 336
[45] Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
Giovannoni, Gavin
Sorensen, Per Soelberg
Cook, Stuart
Rammohan, Kottil W.
Rieckmann, Peter
Comi, Giancarlo
Dangond, Fernando
Hicking, Christine
Vermersch, Patrick
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (06) : 819 - 827
[46] Effectiveness Of Cladribine Tablets In Patients With Relapsing-remitting Multiple Sclerosis With Baseline EDSS ≥3.5 Or ≤3.0 In CLARITY
Comi, G.
Pardo, G.
Dangond, F.
Aldridge, J.
Lemieux, C.
Rammohan, K.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 42 - 43
[47] Cladribine Tablets Demonstrate Similar Efficacy In Male And Female Patients With Relapsing-remitting Multiple Sclerosis In CLARITY
Pardo, G.
Dangond, F.
Aldridge, J.
Lemieux, C.
Bowen, J. D.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 40 - 40
[48] Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study
Comi, Giancarlo
Cook, Stuart
Rammohan, Kottil
Sorensen, Per Soelberg
Vermersch, Patrick
Adeniji, Abidemi K.
Dangond, Fernando
Giovannoni, Gavin
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11 : 1 - 11
[49] Oral cladribine in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRIbine tablets Treating multiple sclerosis orallY) extension study
Giovannoni, G.
Cook, S.
Greenberg, S.
Chang, P.
Comi, G.
Rieckmann, P.
Sorensen, P. Soelberg
Vermersch, P.
JOURNAL OF NEUROLOGY, 2008, 255 : 206 - 206
[50] Effect of cladribine tablets on brain atrophy rates in patients with relapsing-remitting multiple sclerosis (RRMS): exploratory analysis of the CLARITY study
de Stefano, N.
Giorgio, A.
Battaglini, M.
Giovannoni, G.
Hicking, C.
Dangond, F.
Sormani, M. P.
EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 532 - 532

← 1 2 3 4 5 →